The Europe heart valve devices market was valued at USD 3.69 Billion in 2024, driven by the rising prevalence of cardiovascular diseases and increased funding for minimally invasive valve therapies across the region. The market is anticipated to grow at a CAGR of 9.50% during the forecast period of 2025-2034, with the values likely to reach USD 9.14 Billion by 2034. Technological advancements in transcatheter valve replacement and repair systems, are improving outcomes and expanding the eligible patient pool. Moreover, increased clinical adoption of TAVI (transcatheter aortic valve implantation), particularly for high-risk and inoperable patients are aiding growth in the market value.
Base Year
Historical Period
Forecast Period
In December 2024, Meril Life Sciences launched its next-generation Myval Octapro transcatheter heart valve in Europe after receiving CE Mark approval. Such innovations are expected to drive market growth by enhancing TAVR outcomes.
One of the key trends in the market is the rising approval of innovative transcatheter mitral valve implants. For example, in April 2025, Edwards Lifesciences received CE Mark for its Sapien M3 system, the first transfemoral transcatheter mitral valve replacement.
The continuous innovation, strategic collaborations, and efforts to introduce advanced valve technologies are intensifying competition among key players, thereby accelerating growth and enhancing the overall development of the Europe heart valve devices market.
Value in USD Billion
2025-2034
Europe Heart Valve Devices Market Outlook
*this image is indicative*
Heart valve devices are medical implants designed to repair or replace damaged heart valves, ensuring proper blood flow direction and preventing complications such as valve stenosis or regurgitation. The market for heart valve devices in Europe is expanding due to the rising prevalence of cardiovascular diseases, an increasing aging population, advancements in transcatheter technologies, and growing preference for minimally invasive surgical procedures. It is anticipated to grow at a CAGR of 9.50% during the forecast period of 2025-2034.
Rising Cardiovascular Disease Burden to Drive the Market Expansion
The increasing prevalence of cardiovascular disease (CVD) remains a key growth driver in the heart valve devices market in Europe. As reported by the World Heart Federation, CVD is the leading cause of death in the European Union, impacting over 60 million people and resulting in more than 1.7 million deaths annually. This rising prevalence continues to propel demand for advanced heart valve interventions, supporting sustained market growth across the region.
Some of the notable trends include rising funding for minimally invasive therapies:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Valve Type
Market Breakup by Product Type
Market Breakup by Procedure
Market Breakup by End User
Market Breakup by Region
Biological Valves are Expected to Lead the Valve Type Segment
Based on valve types, the market is divided into biological (tissue) valves and mechanical valves. Biological valves will likely to dominate the segment due to their enhanced safety profile, reduced need for lifelong anticoagulation, and growing adoption among elderly patients. Together, these factors are driving the increasing preference for tissue-based valves across surgical and transcatheter procedures.
Segmentation by Product Type to Witness Growth in the Market
Based on the product type, the market is segmented into replacement devices (mechanical valve, bioprosthetic valve, transcatheter aortic valve replacement) and repair devices (surgical valve, transcatheter mitral valve replacement, balloon valvuloplasty devices). Replacement devices are expected to witness substantial growth, primarily due to the rapid adoption of TAVR and rising prevalence of aortic valve disorders.
Minimally Invasive Surgeries to Dominate Procedure Segment
The market share by procedure includes open surgeries and minimally invasive surgeries (MIS). Minimally invasive surgery is projected to lead the segment, supported by technological advancements, faster recovery times, reduced complications, and increasing patient demand. Together, these advantages contribute to its expanding adoption in both replacement and repair interventions.
Hospitals to Lead the End User Segmentation in the Europe Heart Valve Devices Market
Hospitals, ambulatory surgical centers (ASCs), and others together make up the end-user segmentation. Hospitals are expected to hold the largest share due to their comprehensive care capabilities, access to advanced technologies, and availability of specialized cardiac teams. Together, these factors ensure hospitals remain the primary centers for heart valve procedures.
The market is divided into regions such as the United Kingdom, Germany, France, Italy, and others. The United Kingdom is likely to dominate the market, driven by advanced healthcare infrastructure, rising cardiovascular disease incidence, and increasing adoption of transcatheter procedures. Germany holds a significant share due to its strong medical technology sector, while the France benefit from government support and growing demand for minimally invasive treatments.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Medtronic plc, established in 1949 and headquartered in the United States, is a global leader in healthcare technology with a strong presence in the European heart valve devices market. In October 2024, the company launched the Avalus Ultra Bioprosthesis valve in Western Europe. This next-generation surgical aortic valve, designed for enhanced durability and ease of implantation, builds on a decade of clinical success with the Avalus valve. Medtronic’s expanding cardiac surgery portfolio highlights its commitment to advancing cardiovascular care across the region.
Headquartered in Irvine, California, and established in 1958, Edwards Lifesciences Corporation is a leading innovator in structural heart therapies. In May 2024, the company expanded its presence in the Europe heart valve devices market by launching the Sapien 3 Ultra Resilia valve, a transcatheter aortic valve featuring Resilia tissue technology that enhances durability and reduces calcification. With CE Mark approval, this advanced device addresses native aortic stenosis and failed bioprosthetic valves across all surgical risk levels. Edwards' strategic focus on innovation and patient-centric care reinforces its strong market position and supports growing demand for minimally invasive valve replacement options in Europe.
Abbott is a leader in innovative healthcare solutions, including cardiovascular devices. It is headquartered in Illinois, United States and was established in 1888. Abbott's TriClip transcatheter edge-to-edge repair (TEER) system, approved by the FDA in April 2024, is designed for treating tricuspid regurgitation. This minimally invasive device has shown positive results in improving patients' quality of life and reducing symptoms. Abbott's commitment to advancing structural heart therapies, including the MitraClip and Navitor systems, reinforces its strong position in the European heart valve devices market.
Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific Corporation is a leading global medical technology company. In August 2024, it received CE mark approval for its Acurate Prime aortic valve system, an advanced transcatheter aortic valve replacement (TAVR) device designed for patients with severe aortic stenosis. This next-generation valve expands treatment options for larger anatomies and enhances procedural accuracy through a redesigned deployment system.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Corcym Group, B. Braun SE, Getinge AB, Shockwave Medical Inc. (Johnson & Johnson, Services Inc.), JenaValve Technology, Inc., and Xeltis.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Valve Type |
|
| Breakup by Product Type |
|
| Breakup by Procedure |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share